Danaher Corporation claims to be the leading player in bioprocessing and hopes to strengthen the offering further in 2022 through opportunist acquisitions. In 2021, Danaher Corporation spent over $10 billion in M&A deals. The bulk of the capital – $9.6 billion – was used to enter the contract development and manufacturing organization (CDMO) through the addition of Aldevron, though other deals in the life sciences space included the addition of lipid nanoparticle tech firm Precision Nanosystems (PNI). And discussing the…